
What We're Reading: Should the FDA Change How Drugs Are Approved in the US?
What we're reading, June 30, 2016: one doctor makes the case for the FDA moving away from a simple approval/no approval system; Massachusetts and Gilead come to an agreement over hepatitis C drug rebates; and Georgia considers Medicaid expansion.
In a
Massachusetts and Gilead Sciences have come to an agreement over hepatitis C treatments. The state was threatening to sue the company over the cost of the drugs, but have reached a deal for the state to receive rebates fo most residents with the disease,
Georgia could following in Louisiana’s footsteps regarding Medicaid expansion.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.